Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GED 0507-34-Levo

Drug Profile

GED 0507-34-Levo

Alternative Names: GED-0507; GED-0507-34; N-acety-GED-0507-34

Latest Information Update: 28 Jan 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Giuliani
  • Developer Nogra Pharma; PPM services
  • Class Anti-inflammatories; Antiulcers
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris
  • Preclinical Idiopathic pulmonary fibrosis
  • No development reported Ulcerative colitis

Most Recent Events

  • 28 Jan 2021 No recent reports of development identified for phase-I development in Acne-vulgaris(In adolescents, In children, In adults) in Italy (Topical)
  • 01 Nov 2018 Pharmacodynamics data from preclinical trial in idiopathic pulmonary fibrosis presented at the 28th Annual Congress of the European Respiratory Society (ERS - 2018)
  • 15 Sep 2018 Preclinical trials in Idiopathic pulmonary fibrosis in Ireland (PO) prior to September 2018
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top